{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:46Z","timestamp":1792788226221,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianjin Key Medical Discipline ( Specialty ) Construction Project","award":["TJYXZDXK-037A"],"award-info":[{"award-number":["TJYXZDXK-037A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03596-y","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:55:34Z","timestamp":1764608134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aqueous humor cytokine levels in retinal vein occlusion patients with suboptimal response to anti-VEGF therapy and the correlation with OCT imaging biomarkers"],"prefix":"10.1186","volume":"31","author":[{"given":"Yi","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongguo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"1","key":"3596_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ophtha.2010.04.019","volume":"118","author":"SS Hayreh","year":"2011","unstructured":"Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology. 2011;118(1):119-133 e1-2. https:\/\/doi.org\/10.1016\/j.ophtha.2010.04.019.","journal-title":"Ophthalmology"},{"issue":"1","key":"3596_CR2","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.010427","volume":"9","author":"P Song","year":"2019","unstructured":"Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019;9(1):010427. https:\/\/doi.org\/10.7189\/jogh.09.010427.","journal-title":"J Glob Health"},{"key":"3596_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113457","author":"H Noma","year":"2020","unstructured":"Noma H, Yasuda K, Shimura M. Cytokines and pathogenesis of central retinal vein occlusion. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9113457.","journal-title":"J Clin Med"},{"key":"3596_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10225300","author":"A Grzybowski","year":"2021","unstructured":"Grzybowski A, Markeviciute A, Zemaitiene R. Treatment of macular edema in vascular retinal diseases: a 2021 update. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10225300.","journal-title":"J Clin Med"},{"key":"3596_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2147\/OPTH.S163859","volume":"12","author":"JM Jumper","year":"2018","unstructured":"Jumper JM, Dugel PU, Chen S, Blinder KJ, Walt JG. Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2). Clin Ophthalmol. 2018;12:621\u20139. https:\/\/doi.org\/10.2147\/OPTH.S163859.","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"3596_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jamaophthalmol.2021.5619","volume":"140","author":"S Gurudas","year":"2022","unstructured":"Gurudas S, Patrao N, Nicholson L, et al. Visual outcomes associated with patterns of macular edema resolution in central retinal vein occlusion treated with anti-vascular endothelial growth factor therapy: a post hoc analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial. JAMA Ophthalmol. 2022;140(2):143\u201350. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.5619.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"3596_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/ICB.0000000000000768","volume":"15","author":"A Modi","year":"2021","unstructured":"Modi A, Sharma K, Sudhakar NP, Yadav NK. Aqueous humor cytokines and therapeutic customization in nonresponding macular edema secondary to retinal vein occlusion. Retin Cases Brief Rep. 2021;15(2):127\u201330. https:\/\/doi.org\/10.1097\/ICB.0000000000000768.","journal-title":"Retin Cases Brief Rep"},{"issue":"4","key":"3596_CR8","doi-asserted-by":"publisher","first-page":"e891","DOI":"10.1111\/aos.15008","volume":"100","author":"J Mao","year":"2022","unstructured":"Mao J, Zhang S, Zheng Z, et al. Prediction of anti-VEGF efficacy in diabetic macular oedema using intraocular cytokines and macular optical coherence tomography. Acta Ophthalmol. 2022;100(4):e891\u20138. https:\/\/doi.org\/10.1111\/aos.15008.","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"3596_CR9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/aos.14621","volume":"99","author":"M Michl","year":"2021","unstructured":"Michl M, Liu X, Kaider A, Sadeghipour A, Gerendas BS, Schmidt-Erfurth U. The impact of structural optical coherence tomography changes on visual function in retinal vein occlusion. Acta Ophthalmol. 2021;99(4):418\u201326. https:\/\/doi.org\/10.1111\/aos.14621.","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"3596_CR10","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41433-022-02265-2","volume":"37","author":"S Arepalli","year":"2023","unstructured":"Arepalli S, Wykoff CC, Abraham JR, et al. Longitudinal analysis of aqueous humour cytokine expression and OCT-based imaging biomarkers in retinal vein occlusions treated with anti-vascular endothelial growth factor therapy in the IMAGINE study. Eye Lond. 2023;37(9):1928\u201335. https:\/\/doi.org\/10.1038\/s41433-022-02265-2.","journal-title":"Eye Lond"},{"issue":"1","key":"3596_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00417-024-06579-7","volume":"263","author":"G Spital","year":"2025","unstructured":"Spital G, Schmitz-Valckenberg S, Muller B, et al. Interpretation of SD-OCT imaging data in real-life conditions versus standardized reading centre analysis in eyes with diabetic macular oedema or macular oedema secondary to retinal vein occlusion: 24-month follow-up of the ORCA study. Graefes Arch Clin Exp Ophthalmol. 2025;263(1):131\u20139. https:\/\/doi.org\/10.1007\/s00417-024-06579-7.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3596_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58070933","author":"Y Yamada","year":"2022","unstructured":"Yamada Y, Takamura Y, Matsumura T, Gozawa M, Morioka M, Inatani M. Regional variety of reduction in retinal thickness of diabetic macular edema after anti-VEGF treatment. Medicina (Kaunas). 2022. https:\/\/doi.org\/10.3390\/medicina58070933.","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"3596_CR13","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1136\/bjo-2024-325665","volume":"109","author":"J Ruiz-Medrano","year":"2025","unstructured":"Ruiz-Medrano J, Udaondo Mirete P, Fernandez-Jimenez M, et al. Biomarkers of risk of switching to dexamethasone implant for the treatment of diabetic macular oedema in real clinical practice: a multicentric study. Br J Ophthalmol. 2025;109(10):1155\u201360. https:\/\/doi.org\/10.1136\/bjo-2024-325665.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"3596_CR14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00417-021-05387-7","volume":"260","author":"E Maggio","year":"2022","unstructured":"Maggio E, Mete M, Sartore M, et al. Temporal variation of optical coherence tomography biomarkers as predictors of anti-VEGF treatment outcomes in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2022;260(3):807\u201315. https:\/\/doi.org\/10.1007\/s00417-021-05387-7.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"3596_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.18240\/ijo.2024.02.11","volume":"17","author":"DS Li","year":"2024","unstructured":"Li DS, Liao HX, Zhang JL, Qin B. Effect of aflibercept combined with triamcinolone acetonide on aqueous humor growth factor and inflammatory mediators in diabetic macular edema. Int J Ophthalmol. 2024;17(2):297\u2013303. https:\/\/doi.org\/10.18240\/ijo.2024.02.11.","journal-title":"Int J Ophthalmol"},{"issue":"5","key":"3596_CR16","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1442-9071.2009.02061.x","volume":"37","author":"SP Park","year":"2009","unstructured":"Park SP, Ahn JK. Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Clin Exp Ophthalmol. 2009;37(5):490\u20135. https:\/\/doi.org\/10.1111\/j.1442-9071.2009.02061.x.","journal-title":"Clin Exp Ophthalmol"},{"issue":"3","key":"3596_CR17","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1111\/aos.14248","volume":"98","author":"QY Yi","year":"2020","unstructured":"Yi QY, Wang YY, Chen LS, et al. Implication of inflammatory cytokines in the aqueous humour for management of macular diseases. Acta Ophthalmol. 2020;98(3):e309\u201315. https:\/\/doi.org\/10.1111\/aos.14248.","journal-title":"Acta Ophthalmol"},{"key":"3596_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06695-4","author":"V Chaudhary","year":"2024","unstructured":"Chaudhary V, Mar F, Amador MJ, et al. Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases. Graefes Arch Clin Exp Ophthalmol. 2024. https:\/\/doi.org\/10.1007\/s00417-024-06695-4.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"3596_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05441-y","volume":"22","author":"L Sha","year":"2024","unstructured":"Sha L, Zhao Y, Li S, Wei D, Tao Y, Wang Y. Insights to Ang\/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases. J Transl Med. 2024;22(1):898. https:\/\/doi.org\/10.1186\/s12967-024-05441-y.","journal-title":"J Transl Med"},{"issue":"12","key":"3596_CR20","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.13.12.35","volume":"13","author":"M Shimura","year":"2024","unstructured":"Shimura M, Sasaki S, Nonaka R, et al. Changes in aqueous Angiopoietin-1\/2 concentrations during the induction phase of intravitreal faricimab injections for diabetic macular edema. Transl Vis Sci Technol. 2024;13(12):35. https:\/\/doi.org\/10.1167\/tvst.13.12.35.","journal-title":"Transl Vis Sci Technol"},{"issue":"14","key":"3596_CR21","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.65.14.46","volume":"65","author":"KL Huber","year":"2024","unstructured":"Huber KL, Stino H, Steiner I, et al. Real-world outcomes after switch from aflibercept to faricimab in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci. 2024;65(14):46. https:\/\/doi.org\/10.1167\/iovs.65.14.46.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3596_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2025.03.005","author":"CJ Danzig","year":"2025","unstructured":"Danzig CJ, Dinah C, Ghanchi F, et al. Faricimab treat-and-extend dosing for macular edema due to retinal vein occlusion: 72-Week Results From the BALATON and COMINO Trials. Ophthalmol Retina. 2025. https:\/\/doi.org\/10.1016\/j.oret.2025.03.005.","journal-title":"Ophthalmol Retina."},{"issue":"1","key":"3596_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00586-w","volume":"10","author":"G Grimaldi","year":"2024","unstructured":"Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M. Intravitreal faricimab for treatment naive patients with neovascular age-related macular degeneration: a real-world prospective study. Int J Retina Vitreous. 2024;10(1):70. https:\/\/doi.org\/10.1186\/s40942-024-00586-w.","journal-title":"Int J Retina Vitreous"},{"key":"3596_CR24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ajo.2024.08.040","volume":"269","author":"JT Ramo","year":"2025","unstructured":"Ramo JT, Kim LA, Stryjewski T, et al. Targeting the Tie-2 receptor with faricimab in central serous chorioretinopathy: a case series motivated by a genetic finding. Am J Ophthalmol. 2025;269:246\u201354. https:\/\/doi.org\/10.1016\/j.ajo.2024.08.040.","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"3596_CR25","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1007\/s00417-021-05211-2","volume":"259","author":"H Yong","year":"2021","unstructured":"Yong H, Qi H, Yan H, Wu Q, Zuo L. The correlation between cytokine levels in the aqueous humor and the prognostic value of anti-vascular endothelial growth factor therapy for treating macular edema resulting from retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2021;259(11):3243\u201350. https:\/\/doi.org\/10.1007\/s00417-021-05211-2.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3596_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-025-06738-4","author":"Y Arai","year":"2025","unstructured":"Arai Y, Takahashi H, Inoda S, Sakamoto S, Kawashima H, Yanagi Y. Effectiveness and cytokine profile of combined anti-vascular endothelial growth factor and corticosteroid therapy for chronic retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2025. https:\/\/doi.org\/10.1007\/s00417-025-06738-4.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"3596_CR27","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1038\/s41433-024-03015-2","volume":"38","author":"YJ Sepah","year":"2024","unstructured":"Sepah YJ, Do DV, Mesquida M, et al. Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy. Eye Lond. 2024;38(9):1755\u201361. https:\/\/doi.org\/10.1038\/s41433-024-03015-2.","journal-title":"Eye Lond"},{"issue":"2","key":"3596_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4103\/ijo.IJO_1280_22","volume":"71","author":"GS Pillai","year":"2023","unstructured":"Pillai GS, Gupta A, Xavier T, et al. Effect of dexamethasone implant on intraocular cytokines in diabetic macular edema. Indian J Ophthalmol. 2023;71(2):363\u20138. https:\/\/doi.org\/10.4103\/ijo.IJO_1280_22.","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"3596_CR29","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1111\/aos.12219","volume":"92","author":"HJ Sohn","year":"2014","unstructured":"Sohn HJ, Han DH, Lee DY, Nam DH. Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion. Acta Ophthalmol. 2014;92(3):e217\u201324. https:\/\/doi.org\/10.1111\/aos.12219.","journal-title":"Acta Ophthalmol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03596-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03596-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03596-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:03:14Z","timestamp":1767679394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03596-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3596"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03596-y","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}